In patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC) disease progression occurs after a median of 9-10 months of crizotinib treatment. Several mechanisms of resistance have been identified and include ALK mutations and amplification or the activation of bypassing signaling pathways. Re-biopsy in NSCLC patients represents a critical issue and the analysis of circulating cell-free DNA (cfDNA) has a promising role for the identification of resistance mechanisms.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pY5CvB
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Pycnodysostosis is a rare autosomal, recessive, skeletal dysplasia caused by a mutation in the cathepsin k gene. Pycnodysostosis is characte...
-
2016-12-10T02-17-59Z Source: Indo American Journal of Pharmaceutical Research Radha S & Sreelatha .S*. Research has demonstrated th...
-
ACS Nano DOI: 10.1021/acsnano.7b01783 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2trY7nv via...
-
2016-10-22T03-07-52Z Source: International Journal of Community Medicine and Public Health Ketan R. Dagdiya, Sushma S. Thakre, Subhash B....
-
Need Industrial relations advice? Unfair dismissals laws? Discrimination in the workplace? Sexual harassment? We can help. AWNA is Australia...
-
by Javier U. Chicote, Rob DeSalle, José Segarra, Tung-Tien Sun, Antonio García-España from #AlexandrosSfakianakis via Alexandros G.Sfakia...
-
Vol.28 No.1 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QLVDop via IFTTT
-
Participant Experiences of Attending a Community CBT Workshop for Insomnia: A Qualitative Six-Year Follow-Up. Behav Sleep Med. 2017 Ap...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου